U.S. markets close in 11 minutes
  • S&P 500

    4,142.62
    -2.57 (-0.06%)
     
  • Dow 30

    32,865.93
    +62.46 (+0.19%)
     
  • Nasdaq

    12,646.58
    -10.98 (-0.09%)
     
  • Russell 2000

    1,940.59
    +18.76 (+0.98%)
     
  • Crude Oil

    90.59
    +1.58 (+1.78%)
     
  • Gold

    1,786.40
    +13.50 (+0.76%)
     
  • Silver

    20.62
    +0.78 (+3.95%)
     
  • EUR/USD

    1.0195
    +0.0007 (+0.07%)
     
  • 10-Yr Bond

    2.7650
    -0.0750 (-2.64%)
     
  • GBP/USD

    1.2071
    +0.0001 (+0.01%)
     
  • USD/JPY

    135.0780
    +0.1080 (+0.08%)
     
  • BTC-USD

    23,942.34
    +737.26 (+3.18%)
     
  • CMC Crypto 200

    558.80
    +15.93 (+2.93%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Ayala's Cancer Candidate Shrinks Tumor In Substantially All Patients In Late-Stage Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Ayala Pharmaceuticals Inc (NASDAQ: AYLAannounced interim results from Part A of the ongoing RINGSIDE Phase 2/3 trial evaluating AL102 in desmoid tumors.

  • MRI scans showed decreases in tumor size in most of the 13 patients who had reached the 16-week point.

  • One patient reached an unconfirmed partial response at week 16.

  • AL102 was well tolerated at all dose levels with no dose-limiting toxicities, and no Grade 4/5 adverse events were observed.

  • Also Read: Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101.

  • The most common treatment-related adverse events were Grade 1-2, including diarrhea, fatigue, skin rash, and nausea.

  • "We are also encouraged with the safety data showing that AL102 appears well tolerated. We look forward to presenting a more advanced and comprehensive data set at a medical meeting later in the year," said Roni Mamluk, CEO of Ayala.

  • "The results from Part A will be used to determine the dose of AL102 to be evaluated in Part B of RINGSIDE, which Ayala is on track to initiate in Q3 of 2022," the CEO added.

  • Price Action: AYLA shares are down 2.05% at $1.09 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.